�this negligence must not be allowed to continue,� budkie�s letter states. �the university of california, berkeley, has clearly failed to follow federal regulations and guidelines.�
.
. updated on:
.
.
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
harvard medical school: "cgrp: a new era for migraine treatment."
.